Bio Aegis Therapeutics
Biotechnology, 6 E Cove Ln, North Brunswick, New Jersey, 07960, United States, 11-50 Employees
Phone Number: 97********
Who is BIOAEGIS THERAPEUTICS
Commercializing Ground Breaking Discoveries in Inflammation and Infection BioAegis Therapeutics products restore plasma gelsolin, a human protein, whose important clinical role has been s...
Read More
-
Headquarters: 6 E Cove Ln, North Brunswick, New Jersey, 07960, United States
-
Date Founded: 2011
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2833
|
NAICS Code: 325411 |
Show More
Does something look wrong? Fix it. | View contact records from BIOAEGIS THERAPEUTICS
BioAegis Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding BioAegis Therapeutics
Answer: BioAegis Therapeutics's headquarters are located at 6 E Cove Ln, North Brunswick, New Jersey, 07960, United States
Answer: BioAegis Therapeutics's phone number is 97********
Answer: BioAegis Therapeutics's official website is https://bioaegistherapeutics.com
Answer: BioAegis Therapeutics's revenue is $1 Million to $5 Million
Answer: BioAegis Therapeutics's SIC: 2833
Answer: BioAegis Therapeutics's NAICS: 325411
Answer: BioAegis Therapeutics has 11-50 employees
Answer: BioAegis Therapeutics is in Biotechnology
Answer: BioAegis Therapeutics contact info: Phone number: 97******** Website: https://bioaegistherapeutics.com
Answer: Commercializing Ground Breaking Discoveries in Inflammation and Infection BioAegis Therapeutics products restore plasma gelsolin, a human protein, whose important clinical role has been studied in animals and humans. Based on discoveries by Dr. Thomas Stossel and others, the bodys natural reservoir of plasma gelsolin keeps inflammation local, while its deficiency leads to inflammatory dysregulation and catastrophic consequences like multiple organ failure, shock and death. Systemic inflammation causes morbidity and mortality in a myriad of diseases including rare orphan indications and major acute and chronic diseases such as trauma, burns, renal disease and sepsis. Replacement of plasma gelsolin holds great promise for patients suffering from severe conditions with high unmet medical needs. BioAegis is developing high value, biomarker-directed treatments across a range of indications.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month